Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Validation for PDCs

<< Previous

Bullboard Posts

Next >>

Comment by Joemareon Mar 29, 2023 12:51pm

89 Views

Post# 35367217

RE:Validation for PDCs

As days go by in March, not sure where we stand with the peptide. But one thing is for sure:
Making a deal at Pfizer when every biotech company knocks at your door vs. you knocking at other biotenchs/pharma is not the same game. Not the same set of skills. 3 years, zero deals. It's not only about the science. It's also about the guy that makes the deal.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record